^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Title:

Management of Male Breast Cancer: ASCO Guideline

Published date:
02/14/2020
Excerpt:
Recommendation...Men with advanced or metastatic, hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer should be offered endocrine therapy as first-line therapy except in cases of visceral crisis or rapidly progressive disease. Options include tamoxifen, an aromatase inhibitor with a gonadotropin-releasing hormone agent, and fulvestrant.
DOI:
10.1200/JCO.19.13120